Why was the output on an Aveir VR leadless pacemaker increased from 4.0V to 5.0V?

The output was increased because the capture threshold rose to 3.5V/0.4ms, leaving a critically thin safety margin of only 1.14:1 at the previous 4.0V setting. In a pacing-dependent patient with complete heart block and 91% RV pacing burden, any threshold fluctuation could result in life-threatening loss of capture.

How does increasing Aveir VR output to 5.0V affect battery longevity?

Increasing RV pulse amplitude from 4.0V to 5.0V at 91% pacing burden reduced projected battery longevity by approximately 1.7 years — from ~5.2 years to 3.4 years — as documented in the Abbott Merlin wrap-up data.

What does a rising capture threshold in a leadless pacemaker indicate?

A progressive increase in capture threshold (e.g., 2.75V to 3.5V over 7 weeks) can reflect fibrotic encapsulation at the device-tissue interface, micro-dislodgement, or chronic electrode deterioration. It is an important indicator for monitoring and may strengthen candidacy for device upgrade or LBBAP.

Aveir VR Leadless Pacemaker: Rising Capture Threshold & Battery Longevity Analysis

A pacing-dependent patient with complete heart block and ~91% RV pacing burden on an Abbott Aveir VR leadless pacemaker (LSP112V, implanted May 2024) underwent an in-clinic device interrogation at Cleveland Clinic Weston on April 7, 2026. The encounter revealed a rising capture threshold, a consequential output adjustment, and significant battery longevity implications — all with direct bearing on LBBAP upgrade candidacy.

Clinical Background

The patient is a 71-year-old male with complete heart block implanted with an Abbott Aveir VR leadless pacemaker (serial 1330669) on May 8, 2024, followed by Dr. Parikshit S. Sharma at Cleveland Clinic Florida. The device is programmed in VVI mode at 50 bpm, with rate-responsive function active (Max Sensor Rate 130 bpm). With 91% ventricular pacing burden, the patient is effectively pacemaker-dependent, meaning any loss of capture carries immediate hemodynamic consequences.

The Clinical Question: Why Was Output Increased Without Patient Notification?

The Cleveland Clinic encounter summary noted: "Output adjusted from 3.5V to 5V per Dr. Sharma." However, the original Abbott Merlin Wrap-up Overview reveals a more precise — and clinically important — picture: the change was from 4.0V → 5.0V, not from 3.5V.

⚠ Clinical Note

The Cleveland Clinic summary inaccurately stated the output was changed from 3.5V to 5.0V. The Abbott device printout confirms the actual change was from 4.0V to 5.0V. This discrepancy matters for reconstructing the safety margin history.

Why the Output Change Was Clinically Justified

The capture threshold at the April 7, 2026 encounter was 3.5V @ 0.4ms. With the device previously programmed at 4.0V, the safety margin was only 1.14:1 — far below the conventionally recommended 2:1 ratio. In a pacing-dependent patient, threshold fluctuations due to autonomic tone, metabolic changes, fever, or medication effects could produce intermittent loss of capture with no intrinsic rhythm backup. The output increase to 5.0V restored a more defensible (though still suboptimal) margin of approximately 1.43:1.

What was unjustifiable, however, was the absence of any discussion with the patient regarding the rationale, the implications for battery longevity, or the connection to a potential device upgrade decision.

The Capture Threshold Trend: A Worrying Trajectory

Cross-referencing the Abbott Test Results data from two dates reveals a clinically significant threshold escalation:

Date	Capture Threshold	Pulse Width	R-Wave Sense	Impedance
Feb 13, 2026	2.75 V	0.4 ms	4.3 mV	600 Ω
Apr 7, 2026	3.5 V ↑	0.4 ms	4.5 mV	610 Ω

The threshold increased by 0.75V in approximately 7 weeks. This rate of escalation is abnormal in the chronic phase (>6 months post-implant) and may indicate progressive fibrotic encapsulation at the device-tissue interface, micro-dislodgement, or electrode deterioration. If the trend continues at this rate, the threshold could approach 5.0V by mid-summer 2026, at which point the newly programmed 5.0V output would provide zero safety margin.

Battery Longevity: Real-Time Impact Documented

The Abbott Merlin PCS system generates sequential battery longevity estimates throughout the interrogation session. The data from April 7, 2026 shows a dramatic, real-time impact of the output change:

Session Time	Output Setting	Projected Longevity	Battery Voltage
13:39	4.0 V / 0.4 ms	5.1 yrs	3.0 V
13:41	4.0 V / 0.4 ms	5.2 yrs	3.0 V
13:44	4.0 V / 0.4 ms	5.2 yrs	3.0 V
13:47 (post-change)	5.0 V / 0.4 ms	3.4 yrs ↓	3.0 V
13:49	5.0 V / 0.4 ms	3.4 yrs	3.0 V

The single output change from 4.0V to 5.0V reduced projected battery life by approximately 1.7 years — from ~5.2 to 3.4 years. With RRT projected for approximately mid-2029 and a still-rising capture threshold, actual battery longevity may be shorter than currently estimated.

Summary of Key Findings — April 7, 2026 Encounter

Capture threshold rose from 2.75V (Feb 13) to 3.5V (Apr 7) — +0.75V in 7 weeks
Output increased from 4.0V → 5.0V per physician order (not 3.5V as documented in summary)
Safety margin at 5.0V/3.5V threshold = 1.43:1 (suboptimal; standard target ≥2:1)
Battery longevity dropped from 5.2 years to 3.4 years immediately post-change
R-wave amplitude: 4.5 mV (down from prior ~6 mV — declining trend)
Impedance stable: 610 Ω (600 Ω in Feb — no significant change)
RV pacing burden: 91% — effectively pacemaker-dependent
No arrhythmic episodes recorded; no therapy delivered

Implications for LBBAP Upgrade Candidacy

Left Bundle Branch Area Pacing (LBBAP) has emerged as the preferred physiologic pacing strategy for patients at high risk for or already demonstrating pacing-induced cardiomyopathy (PICM). For leadless pacemaker patients requiring upgrade, LBBAP via a transvenous lead offers superior ventricular synchrony, lower pacing thresholds, and avoidance of progressive right ventricular dyssynchrony.

The April 7, 2026 interrogation data collectively strengthens the clinical argument for timely LBBAP upgrade evaluation:

1. Rising Threshold Reduces Device Longevity Runway

With RRT now projected for ~mid-2029 and threshold still climbing, the practical window for elective upgrade planning is narrowing. A planned upgrade under controlled circumstances is preferable to emergency management of a failing leadless device in a pacing-dependent patient.

2. Marginal Safety Margin at Current Output

A 1.43:1 safety margin (5.0V output vs. 3.5V threshold) is insufficient for a patient with 91% RV pacing burden and CHB. Any further threshold elevation — expected given the trajectory — reduces this margin to critically dangerous levels.

3. Progressive Echocardiographic Remodeling

Serial echocardiographic data showing progressive LV remodeling and LA dilation, combined with a chronically elevated high-sensitivity troponin T, represent independent clinical indicators of PICM — the central indication for upgrade to physiologic pacing.

4. The Communication Obligation

From an ethical and medicolegal standpoint, programming changes with significant implications — including a 1.7-year reduction in device longevity and the triggering of an upgrade timeline discussion — warrant explicit informed discussion with the patient. This is particularly true when the patient is a physician with the expertise to participate meaningfully in shared decision-making.

FAQ: Aveir VR Capture Threshold and Upgrade Candidacy

Typical chronic capture thresholds for the Aveir VR are reported in the range of 0.5–1.5V at 0.4ms in stable patients. Thresholds above 2.5V in the chronic phase raise concern for suboptimal electrode-tissue contact or progressive encapsulation, and values at or above 3.5V warrant urgent clinical reassessment and consideration of increased output or device upgrade.

Battery current drain increases with output voltage in a nonlinear fashion due to the energy relationship (E = ½CV²). At high pacing burdens (>80%), even modest output increases can subtract 1–2 years from projected longevity. This underscores the importance of optimizing the electrode-tissue interface at implant and addressing rising thresholds proactively before output must be escalated.

LBBAP upgrade should be considered when there is evidence of pacing-induced cardiomyopathy (LVEF decline, LV remodeling, or elevated cardiac biomarkers), progressive capture threshold elevation threatening device longevity, anticipated battery replacement within 3–4 years in a high-burden patient, or patient preference for physiologic pacing. The decision must weigh procedural risk against the ongoing cumulative harm of right ventricular dyssynchrony.

No. Standard electrophysiology practice recommends a minimum 2:1 voltage safety margin (output ≥ 2× threshold). For pacing-dependent patients with no escape rhythm, some experts advocate for even higher margins. A 1.43:1 ratio at 5.0V/3.5V provides inadequate protection against loss of capture during physiologic threshold variations (sleep, fever, autonomic surges, medication effects).

Conclusions

The April 7, 2026 device interrogation of this pacing-dependent Aveir VR patient documents a clinically significant and escalating capture threshold (2.75V → 3.5V over 7 weeks), an output increase that reduced battery longevity by ~1.7 years, and a marginal safety margin that will become untenable if the threshold trend continues. These findings — taken alongside serial echocardiographic evidence of LV remodeling and elevated cardiac biomarkers — constitute a compelling, multi-domain argument for structured LBBAP upgrade evaluation. Patient-physician communication regarding programming decisions with major longevity and upgrade-timing implications is not optional; it is a fundamental component of informed, ethical device management.

Disclaimer: This article is produced for medical education purposes and is intended for qualified healthcare professionals. It does not constitute individualized medical advice. Clinical decisions should be made by the treating physician in consultation with the patient.

Aveir VR Leadless Pacemaker: Rising Capture Threshold, Output Adjustment, and LBBAP Upgrade Candidacy